HTA publishes revised guidance on reporting incidents in the post mortem sector. The Human Tissue Authority (HTA) has issued an update for establishments operating under a post-mortem license about the submission and completion of HTA...
“Today we are publishing data about incidents reported to HTA during quarter three of 2023 to 2024. We are also publishing our workforce and expenses information. HTA licensed establishments in the Post Mortem, Human Application...
The FDA has granted approval for Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis bullosa (DEB) in patients aged six months and above. Vyjuvek is a non-invasive, topical, re-dosable gene therapy that delivers functional human...
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access. Read the press release from Medicines and Healthcare products Regulatory Agency published on 27 January 2023.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access. Read the news from Medicines and Healthcare products Regulatory Agency updated on 24 January 2022.
The way you apply to licence biological products has changed. Read more From Medicines and Healthcare products Regulatory Agency, published 31 December 2020, last updated 10 May 2021.
A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access. Read more News from Medicines and Healthcare products Regulatory Agency, published 30 March 2021, last updated...
